Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | AKTS Aktis Oncology, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $22.86 +0.7% | $15.37 -0.2% |
| StockIQ Score | 45D+ Moderate Risk: High | 35F Weak Risk: High |
| Technical | 27F | 13F |
| Fundamental | — | 35F |
| Growth | — | 50C- |
| Fair Value | — | 38F |
| News | 92A+ | 50C- |
| Quality | — | 50C- |
| Risk | 42D | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Aktis Oncology (AKTS) outperforms Ascentage Pharma (AAPG) in nearly all categories. Its investor score (75 vs. 37) and technical score (77 vs. 18) are significantly stronger, while AAPG’s growth and valuation scores are only available for comparison. AKTS also carries a "STRONG" rating, compared to AAPG’s "WEAK."
